AstraZeneca extends deal-making streak

Share this article:
AstraZeneca said it is buying licensing and research rights to an Alzheimer’s drug, marking the fourth agreement the company has inked in the last month. AstraZeneca said it agreed to pay up to $300 million to Targacept for rights to help develop and market that firm’s phase II compound TC-1734, which is being developed to treat Alzheimer’s disease and schizophrenia. The four-year deal also hands AstraZeneca global rights for the development and commercialization of any compounds that arise out of the research collaboration, namely drugs for treating cognitive decline. The agreement caps a busy month that also included AstraZeneca’s pact worth up to $338 million to develop CytoFab, a treatment for severe infections, with UK biotech company Protherics PLC; a potential $1 billion licensing agreement for an investigational oral drug for the treatment of atherosclerosis from Alpharetta, Ga.-based AtheroGenics; and last week’s $210 million purchase of privately owned UK biotech firm KuDOS Pharmaceuticals, in which AZ acquired promising Phase I cancer compound KU59436. Analysts haven’t ruled out further deals in the coming months. Under the Targacept agreement, Winston-Salem, N.C.-based Targacept, which specializes in drugs for CNS disorders, receives an initial payment of $10 million and could get additional milestone and research-support payments and royalties dependent on sales of TC-1734.
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.